Prof. Bernard C. Rossier

Ms Marie-Madeleine
+41 22 704 36 41


Chemin Rieu 17
P.O. Box 270
1211 Geneva 17
+41 22 704 36 36
+41 22 704 36 37


Owen J. Sansom

The Beatson Institute for Cancer Research, Glasgow, Scotland (UK)

Wednesday, October 24, 10:30 - 11:00

mTOR signalling in murine models of colorectal cancer

Colorectal cancer (CRC) is a cancer which can be defined by common mutations that drive carcinogenesis. The Apc (adenomatous polyposis coli) gene is mutated in up to 80% of colorectal cancer and thus it is important to find druggable pathways downstream of Apc gene mutation. I will discuss our recent findings showing that:

1) mTORC1 is downstream of Apc loss and  is required for hyperproliferation;

2) KRAS mutation  (which occurs in up to 40% of CRC) removes the dependency of mTORC1 and rewires cells to be dependent on mTORC2;

3) mTORC2 mutation in concert with APC and a PTEN mutation  (30% PTEN or PIK3CA mutation in CRC) accelerates intestinal tumourigenesis.

Taken together these data highlight the importance of classifying the driver mutations in CRC prior to therapeutic intervention in the PI3 kinase/mTOR pathway.


Owen J. Sansom is currently the Deputy Director of CR-UK Beatson Institute for Cancer Research (BICR). He did his PhD with Professors Andrew Wyllie and Alan Clarke studying the role of DNA damage apoptosis in the intestine. From there he moved to Cardiff with Professor Alan Clarke studying the role of the methyl binding domain proteins in cancer. In 2005, he formed his own laboratory in Glasgow where his group focusses on Wnt signalling and colorectal cancer, studying important pathways that drive this disease in vivo.